In the realm of biotech, few companies have captured my attention like Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM). I initially spotlighted this gem in November 2021, and since then, its share price has skyrocketed by over 150%. Meanwhile, the S&P 500 has seen a modest 30% increase. As a seasoned biotech consultant with over 5 years of experience covering the healthcare and pharma sectors, I’ve had the privilege of delving into the intricacies of over 1,000 companies. My investment group, Haggerston BioHealth, offers a unique opportunity for like-minded individuals to invest alongside our model portfolio or access our comprehensive financial models and research. If you’re interested in staying ahead of the curve in pharma, biotech, and healthcare, I invite you to join our community.
As a disclosure, I hold a beneficial long position in GILD through various means, including stock ownership, options, or derivatives. This article is a reflection of my personal opinions and was written independently, without compensation from any external sources. I maintain no business relationships with any companies mentioned in this article. It’s essential to remember that past performance is not a guarantee of future success, and any investment decisions should be made after careful consideration of individual circumstances and risk tolerance.
Leave a Reply